Drug intelligence / Profile preview

Apelin

Development stage
Phase 2
Lead developer
BioAge Labs
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous, Subcutaneous
01

Overview

Apelin is an endogenous peptide ligand for the apelin receptor (APLNR, also known as APJ), a G protein-coupled receptor. It acts as a balanced agonist at APLNR, activating both G-protein and β-arrestin pathways. Apelin plays key roles in cardiovascular physiology, including regulation of blood pressure, stimulation of cardiac contractility, and promotion of angiogenesis. Its cardioprotective effects are attributed to Gi signaling through APLNR, while β-arrestin pathway activation may contribute to detrimental cardiac hypertrophy[1][6]. Apelin administration has been shown to improve recovery after myocardial infarction by enhancing contractile function and reducing cellular injury markers[2]. It induces vasodilation primarily via nitric oxide release from endothelial cells but can also cause vasoconstriction depending on vascular bed and conditions[5][8]. Synthetic analogs and biased agonists targeting the apelin-APLNR axis are under investigation for heart failure and other cardiovascular diseases[1][3].

02

Targets

APLNR (Apelin receptor)

Beyond the preview

Go deeper on Apelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apelin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call